Background: Cardiogenic dysfunction with acute renal failure (ARF) and diuretic drug resistance increases mortality after cardiac surgery with cardiopulmonary bypass (CPB) in adults. Until few years ago, intermittent renal replacement therapy (IRRT) was the only therapeutical strategy proposed to such patients. Few data are available in the literature regarding the use of continuous veno-venous haemofiltration (CVVH) in this clinical context. The aim of our observational study was to evaluate the impact of CVVH strategy on ARF in conjunction with cardiogenic shock after cardiac surgery and on its well-known associated poor outcome. Methods: During the period 2005-2006, we prospectively collected data from our database as we controlled the renal replacement therapy using CVVH (n = 73). We also retrospectively collected data from our computerised database on patients who were treated with IRRT (n = 68, period 2002IRRT (n = 68, period -2003. Among CVVH-treated patients, a multivariate analysis of the data aimed to identify risk factors associated with 30-day mortality. Results: In patients who presented with ARF in conjunction with cardiogenic shock after cardiac surgery, 30-day mortality rate was 59% for the IRRT group and 42% for the CVVH group. Within the CVVH group, the logistic regression and multivariate analyses reported that some variables were associated with higher mortality risk: a score F concerning the urinary output criteria of the RIFLE (risk, injury, failure, loss, end-stage kidney disease) classification (for scores R or I: odds ratio (OR): 0.01, 95% confidence interval (95% CI): 0.02-0.59; p = 0.01), plasma bilirubin (OR: 1.44, 95% CI: 1.12-1.84; p = 0.04), total CVVH duration <50 h over 72 h (>50 h; OR: 0.009, 95% CI: 0.04-0.93; p = 0.01), the need of catecholamine support (OR: 12.88, 95% CI: 1.95-84.96; p = 0.01), tachycardia in the intensive care unit (ICU; OR: 1.64, 95% CI: 1.02-2.65; p = 0.04), surgery duration (<300 min; OR: 0.11, 95% CI: 0.02-0.71; p = 0.02) and combined cardiac surgery (OR: 7.00, 95% CI: 1.29-37.88; p = 0.02). Conclusion: In patients with ARF in conjunction with cardiogenic shock after cardiac surgery, renal replacement therapeutic strategy based on long-lasting CVVH could improve patients' outcome. The identification of risk factors associated with a poor outcome would help to better manage such patients in the ICU. Low total duration of CVVH within the first 72 h was one criteria related to poor outcome. This suggests that CVVH must be initiated as soon as possible when ARF with diuretic resistance occurs in patients after cardiac surgery and continued as long as possible for the first 3 days. #
Introduction
Acute renal failure (ARF) after cardiac surgery has been clearly associated with higher mortality rate in the early postoperative period [1, 2] . Most of the time, ARF is not the single complication following cardiac surgery and is associated either with inflammatory response (systemic inflammatory response syndrome, major sepsis or septic shock) or with cardiogenic dysfunction combined with diuretic drug resistance [3] [4] [5] . It has been recently reported that the association of ARF with cardiogenic shock markedly increased mortality rate after cardiac surgery [6] . Moreover, medical treatments are still weak to significantly improve heartfailure-related morbidity when cardiogenic shock and ARF develop, indicating that other therapeutic strategies such as renal replacement would be useful.
In this clinical context, and until very recently, dialysis such as intermittent renal replacement therapy (IRRT) was the only therapeutical strategy proposed in our unit to treat ARF following cardiac surgery. Nevertheless, it has been suggested that acute IRRT-isolated sessions may be too aggressive, resulting in severe haemodynamic instability.
Thus, continuous veno-venous haemofiltration (CVVH) would seem to be an interesting therapeutic strategy in such a clinical context after cardiac surgery [7] . Continuous extracorporeal techniques have been developed with success for such patients [8] and continuous renal replacement therapy (CRRT) for ARF has been recently reported as required in 1-5% of patients following cardiac surgery with cardiopulmonary bypass (CPB) [9] .
Moreover, from a pathophysiological viewpoint, CVVH based on convection with high ultrafiltration rate would be more efficient compared to renal replacement techniques using diffusion to eliminate not only inflammatory agents but also myocardial depressive factor (MDF) [8] .
Very few data are available in the literature regarding patients treated by CVVH for ARF with diuretic resistance and cardiogenic shock after cardiac surgery. In the early 2000s, CVVH was considered as a method to improve the quality of care regarding ARF by first improving haemodynamic tolerance as compared to IRRT and second by allowing the patient to benefit from a CRRT [10] . In 2004, in our unit, CVVH was determined to be the preferred therapeutic strategy for all patients who would develop ARF with diuretic drug resistance and cardiogenic shock after cardiac surgery.
The aim of this observational study was (1) to prospectively evaluate CVVH over a period of 2 years (2005) (2006) with regard to patients' outcome and mortality rate; (2) within the group of patients who benefited from CVVH, to try to improve the management of such a CVVH therapy in our unit; and (3) to identify risk factors that would help in predicting mortality in patients who developed cardiogenic shock and ARF with diuretic drug resistance after cardiac surgery with CPB.
Materials and methods

Patients
On approval from the ethical committee of our institution, this observational study included compiling prospective data from a computerised database of patients treated with CVVH. In 2004, CVVH gradually replaced IRRT in our postcardiac surgery intensive care unit (ICU) to improve the quality of care provided to such patients [10] and to avoid haemodynamic instability induced by IRRT. Moreover, CVVH was totally managed by intensivists whereas IRRT was previously managed by the department of nephrology in our institution. Therefore, the patients benefitted from the prompt decisions of the intensivists rather than awaiting the action of the nephrology department, especially at the night. Moreover, at the end of 2004, the unit was well equipped with CVVH therapy machines to treat all patients who suffered from this clinical condition. The ICU medical and paramedical team was also well trained in the use of this technique for a period of 1 year during 2004.
For a period of 2 years from January 2005 to December 2006, we prospectively compiled data from a computerised database of patients treated with CVVH after cardiac surgery (Fig. 1) .
For this prospective evaluation, cardiogenic shock was defined as follows: combination of low systolic blood pressure (<90 mmHg), low cardiac index (CI; <2.2 l min À1 m À2 ) and pulmonary capillary wedge pressure (Pcwp) >18 mmHg. The inotropic support (dobutamine infusion above 5 mg kg À1 min À1 ), intra-aortic balloon pump (IABP) or vasopressive agents to maintain both systolic pressure above 80 mmHg and CI above 2 l min À1 m À2 was left to the discretion of the intensivists in charge of the patient.
ARF criteria used in this study were those described in the RIFLE (risk, injury, failure, loss, end-stage kidney disease) classification (Table 1) . Diuretic drug resistance was defined as the lack of response in terms of urinary output that did not exceed 0.5 ml kg À1 h À1 over 6 h ('R' class of the RIFLE classification) despite a first intravenous administration of 80 mg furosemide followed in the absence of clinical response by a maximal intravenous dose of 250 mg furosemide. Moreover, data were not analysed if patients presented with one of the following criteria: age under 18 years, chronic renal dysfunction treated with chronic renal replacement or previous renal transplant before cardiac surgery, cardiac surgery without cardiopulmonary bypass (CPB), cardiac transplantation, circulatory mechanical support not associated with cardiac surgery (Fig. 1) .
Demographic data, type of cardiac surgery, patient's evaluation scores (SAPS II, Apache II, Liano et al.'s score [11] ), biological data (creatinin clearance estimated with the Cockroft formula, urea blood nitrogen) and outcome scores (ICU and in-hospital length of stay, 30-day mortality rate) were collected from our computerised database.
All patients included in this period of time (2005) (2006) were operated by the same cardiac surgery team and were attended to in the ICU by the same team of intensivists. Monitoring was the same for all these cardiac surgery patients, including, in particular, radial artery invasive blood pressure, per-and postoperative cardiac echocardiography and Swan-Ganz monitoring.
We also extracted data retrospectively from our database, from a 2-year period over 2002 and 2003, of those patients who presented the same clinical context of ARF with cardiogenic shock but who were treated by IRRT since CVVH was not available at this time in our unit. However, no statistical comparison was made between both the time periods because the evaluation was retrospective in one population (2002) (2003) , Irvine, CA, USA) through an extracorporeal circuit originating and terminating in the same vein. Ultrafiltration rate was estimated using the patient fluid balance and left to the discretion of the intensivist, but pre-dilution and post-dilution were fixed, respectively, as one-third and two-thirds of the exchange flow per hour. The pump blood flow was adapted to reach a filtration rate of 25-30%. Pressure through the membrane was maintained between 100 and 300 mmHg. Anticoagulation was maintained on continuous heparin infusion. Haemofiltration membranes were used for a maximal period of 48 h and were systematically changed at the end of this period.
'ICU-free days' (IFD) were defined as the number of days spent by each patient out of ICU within the period of the first 30 days after surgery. In the patients' outcome data, the 'zero' value was assigned to the patient who died in the ICU to correctly account for the mortality rate [12] . The 'hospital-free days' (HFD) was defined as the number of days each patient spent out of the hospital within the first 3 months after surgery. The 'zero' value was assigned to the patient who died in hospital.
Intermittent renal replacement therapy (IRRT) technique: 2002-2003
Once criteria of ARF were reached, IRRTwas the preferred technique during the time period 2002-2003. It was initiated and followed up by a specific medical team from the department of nephrology in association with anaesthesiologists. IRRT sessions were scheduled every 2 or 3 days once the patient was considered fit for IRRT. A single-lumen catheter was inserted percutaneously into a large vein allowing intermittent haemofiltration with a Gambro AK 100 machine (Gambro, Lund, Sweden).
Statistical analysis
Pre-, per-and postoperative clinical and biological data and data on renal replacement were extracted from our computerised patient database. Data are expressed as mean and standard deviation (continuous variables) or in percentage (categorical variables). For the data from the CVVH group, we performed a multivariate analysis using a backward step-wise logistic regression to assess variables associated with 30-day mortality following cardiac surgery. To avoid overfitting, we used a conservative approach and included only the significant variables in the univariate analysis ( p value of entry 0.25). Because of the high number of variables retained and the number of patients being too low, we performed an intermediate selection with three analyses: one with variables describing laboratory results (serum lactate level, base excess, platelets, bilirubin, Creactive protein (CRP)), the second with variables describing renal function (creatinin level, blood urea nitrogen, RIFLE UO score) and the third with CVVH therapy (treatment duration, surgery duration, mean elapsed time between cardiogenic shock start and CVVH initiation). At each step of these three Table 1 The RIFLE a classification for acute renal failure [10] . analyses, a reduced model was produced by backward elimination as used in another study [13] . Variables associated with death within 30 days in these three intermediate analyses ( p < 0.05) were all included in a multivariate logistic regression model and eliminated in a backward manner. In the final model, the interactions were tested. The odds ratio and their 95% confidence interval of variables selected by the logistic model were estimated. Goodness-of-fit of the model was assessed using the HosmerLemeshow statistics. Statistical analysis was done using the 9.1. SAS software (SAS Institute; Cary, NC, USA).
GFR criteria
Results
Heart surgery was performed on 3331 patients in 2002-2003 and 3242 in 2005-2006, who met our inclusion criteria in our cardiac surgery unit. The number of patients with cardiogenic shock associated with ARF and diuretic drug resistance was 68 (2.0%) during the first period and 73 (2.3%) during the second period ( p > 0.05).
Patients' demographic data, Euroscore, Parsonnet, APACHE II and SAPS II scores extracted from the IRRT and CVVH groups are reported in Table 2 . Patients in the IRRT group had 7 AE 4 'ICU-free days' and the 30-day mortality rate was 59%. In CVVH group, 'ICU-free days' were 16 AE 6 and the mortality rate was 42%.
The duration of hospital-free days was 4 days longer for the CVVH group as compared to the IRRT group. No statistical analysis was done to compare both the groups since the analysis of the first period was retrospective.
In the CVVH group in the second time period (period 2), there were 23 (32%) women and 50 (68%) men and the mean age of the study population was 71 AE 11 years. The mean Euroscore (ES) and Parsonnet's scores (PS) were 11 AE 3 and 29 AE 12, respectively. Within this population, 16 patients (22%) underwent coronary artery bypass graft surgery, 17 (23%) had valvular surgery, 38 (52%) had combined surgery (coronary artery bypass graft and valvular) and two patients had thoracic aorta surgery. Thirty patients (41%) benefited from emergency procedures. Table 3 presents a comparison of the patient survival versus mortality data in the CVVH group for this period Mean CPB time and the cross-clamp time were similar in both groups.
Complications under CVVH and heparin treatment were as follows: two patients were treated for gastric erosion and bleeding by proton pump inhibitors in the non-survivors group; two patients also showed bleeding complication in the survivors group: one with gastric erosion was treated by proton pump inhibitors, and another with bleeding had to undergo haemostatic surgery. All these complications did occur within CVVH treatment and the first postoperative 72 h. CVVH was continued as needed for these four patients without any heparin treatment.
In the multivariate analysis (Table 4) , variables related to 30-day mortality were: (1) heart rate before starting CVVH: high heart rate was associated with higher mortality rate (odds ratio (OR): 1.64 95% CI (95% CI): 1.02-2.65; p = 0.04), (2) the surgery duration <300 min: the faster the surgery, the lower the mortality (OR: 0.11; 95% CI: 0.02-0.71; p = 0.02), (3) combined surgery-induced higher mortality (OR: 7; 95% CI: 1.29-37.88; p = 0.02), (4) a score R or I of the RIFLE classification was associated with lower mortality (OR: 0.01; 95% CI: 0.02-0.59; p = 0.01), (5) plasmatic bilirubin: the higher level induced higher mortality rate (OR: 1.44 95% CI: 1.12-1.84; p = 0.004) and (6) the need of catecholamine support during the first postoperative 72 h was associated with higher mortality (OR: 12.88; 95% CI: 1.95-84.96; p = 0.01).
Regarding data on CVVH management in intensive care unit, more than 50 h of CVVH over a 72-h period was associated with a lower mortality (OR: 0.20; 95% CI: 0.04-0.93; p = 0.04).
Discussion
The first aim of this study was to evaluate mortality and morbidity after CVVH treatment for ARF following cardiac surgery. The CVVH group presented lower 30-day mortality rate (42% vs 59%) and higher ICU-free days at postoperative day 30 (16 AE 6 vs 7 AE 4 days) as compared to the IRRT group, indicating that the patients' outcome improved when CVVH was used. Since only the data for the second time period were prospectively gathered in our database, and since it was not a comparative, randomised and prospective study in both the groups, we did not perform a statistical comparison between the two groups. The conclusion supporting CVVH use for the treatment of ARF after cardiac surgery, even if clinically interesting and somehow relevant, has to be taken cautiously regarding this lack of statistical comparison. The second part of our study only focussed on the CVVH group to find out if some variables would be associated with a poor patient outcome and to find the criteria to improve the quality of CVVH management in such patients. With regard to the factors associated with a poor outcome in the CVVH group, we noticed that seven variables were significantly and independently associated with higher 30-day mortality in the CVVH group: a score 'F' or more regarding the urinary output criteria of the RIFLE classification, a plasmatic bilirubin >50 mmol l À1 (when CVVH was started), a total duration of CVVH treatment <50 h over 72 h, the need for catecholamine support, tachycardia, long surgery duration and combined cardiac surgery.
Despite major advances reported during the last decade in cardiac surgery (new techniques and materials in surgery, intensive care and ECC management), cardiogenic shock still remains associated with a high mortality rate [3] , and medical therapies do not seem to provide the expected effectiveness. In this context of cardiogenic shock, ARF with resistance to diuretic drugs has been previously observed in 70% of patients and has been reported to be associated with the worst prognosis in those patients [5, 6] . ARF has been described as being influenced by several factors: decreased effective blood volume with impaired renal perfusion, outer medulla hypoperfusion and hypoxia, obstruction of medullary capillaries by endothelial injury [14] . These reactions are exaggerated if patients present with a systemic inflammatory reaction, cytokine release, leucocyte activation and/or production of vasoconstricting agents. Consequences of such biological activations are overhydratation [8] and excessive haemodilution following cardiac surgery. This can lead to accumulation of toxic metabolites that contribute to cardiac dysfunction.
In such patients, IRRT should be avoided for possible induction of the risk of acute haemodynamic disturbances [15] . Instead, a better renal replacement therapy would be CVVH. The main benefit of CVVH is it can be closely adapted to the patient's haemodynamic status over time. Moreover, using the convection principle in CVVH could minimise adverse immunological and pro-inflammatory effects of hyperuraemia and would reduce the plasmatic level of MDF [16] . Those reasons explain why in 2004 our intensive care unit progressively changed from IRRT treatment in such a clinical context to CVVH. We needed to evaluate if CVVH therapy would improve the quality of care and evaluate the results in terms of morbidity and mortality for such patients after cardiac surgery with fluid overload and ARF.
The hypothesis that would explain in our study such a potent impact of CVVH could mainly be related to a continuous and longer lasting for CVVH treatment as renal replacement therapy as compared to IRRT. This would explain the difference in mortality rates and outcome between IRRTand CVVH-treated patients observed in our study.
In several studies conducted in non-surgical patients, it was also reported that the mortality rate of ARF was higher when associated with multiple organ failure (MOF) [11, 17] . In 2005, Di Carlo and Alexander proposed a theory called 'the mediator delivery hypothesis' which explained why using CVVH prior to MOF appeared to produce better prognosis [17] .
Many authors have reported interest in using CVVH to treat congestive cardiac failure; however, previous published data only report small case series analysis and provide insufficient data concerning the haemofiltration dose [3, 5, 18] . Nevertheless, these studies reached several end-points that can be listed as follows:
-First, CVVH treatment intensity is statistically associated with a better prognosis. Bent et al. reported a 40% mortality rate that was significantly lower than the expected 66% compared with the predictive model of Liano or those previously reported in the literature [3, 6, [19] [20] [21] [22] . These authors claimed that the mortality rate was better in their study owing to the use of fixed higher ultrafiltration volumes for CVVH in their study, but they did not correlate these high volumes to the patient's body weight leading to a lack of useful guidelines for clinical practice. In the present study, the ultrafiltration volumes used for CVVH were significantly higher in the patients who survived, but multivariate analysis of our data did not find any correlation with survival. We did not find these results surprising. Indeed, our ultrafiltration volumes were up to 35 ml kg À1 h À1 for all patients; however, it has never been clearly proven in this indication, even if it has been largely suggested, that a very high level of ultrafiltration volumes (up to 50 ml kg À1 h À1 ) was beneficial in terms of survival rate [23] .
Interestingly, it is worth pointing out that increasing the total length of CVVH treatment during the first 72 h following cardiogenic shock is associated with better prognosis. Our results reported 58 AE 13 h of CVVH treatment in the survivor group as compared to 34 AE 18 h in the non-survivor group, and multivariate analysis showed the total duration of CVVH >50 h out of 72 h was correlated with lower mortality risk. Two hypotheses could explain these results: (1) increasing the total duration of CVVH would act on the inflammatory component of the cardiogenic shock by optimising not only convective but also absorptive clearance or (2) the same increase of the total duration of CVVH could allow regulating a patient's hydratation level more easily. -Second, the earlier the CVVH is initiated, the better the prognosis after cardiogenic shock. In a previous observational study, Elahi et al. reported a survival rate significantly lower in patients treated by CVVH very early (0.78 AE 0.2 vs 2.55 AE 2.2 days), and the calculated time of delay was from the end of the cardiac surgery to the set up of CVVH [18] .
In our study, we did not find similar results after univariate and multivariate statistical analyses mainly because of the low number of patients in each group. Moreover, the multivariate analysis of our data showed that F (or worse) UO score in the RIFLE classification and plasma bilirubin level were significantly associated with the mortality rate in our patients, probably since they also are criteria demonstrating both MOF and delayed therapeutic set up.
Several predictive models of mortality after ARF consecutive to cardiac surgery have been published. Bent et al. reported results from an observational study in a very large number of patients, but they included not only cardiogenic shock, but also several other causes of ARF (such as septic shock and ARF without cardiogenic shock) [3] .
Our results only focussed on patients who developed both ARF with diuretic resistance and cardiogenic shock and those included in our study had preoperatively higher risk of postoperative complications. Nevertheless, the mortality rate we obtained in the CVVH group (42%) is similar to the one reported by Bent et al., which was significantly lower than that calculated by Liano et al.'s score [11] .
Our study was performed in a single ICU and was only a descriptive non-randomised historical study that includes several limitations.
The fact that the data collection was retrospective for 2002-2003 and prospective for 2005-2006 would also lead to cautious interpretation of these results, suggesting that CVVH would be a better therapy as compared to IRRT for the treatment of ARF associated with cardiogenic shock after cardiac surgery. The comparison of the two subgroups: survivors and non-survivors within the second time period (2005) (2006) ; the CVVH group) has been conducted on a small number of patients that can lead to a lack of power for statistical analysis. However, it is noteworthy that the goodness-of-fit of this model was correct since the p value was 0.20.
In conclusion, our study suggests that CVVH would be an interesting therapeutical strategy to treat ARF following cardiac surgery instead of IRRT. Multivariate analysis performed on the data from patients with ARF and cardiogenic shock after cardiac surgery with CPB and treated with CVVH led to point out some clinical, therapeutic and biological data that would help in the evaluation of the mortality risk of such patients. It showed that the following criteria were correlated with a worse 30-day mortality rate: F UO score in the RIFLE classification, high plasma bilirubin level (the higher the level, the worst the outcome), low total duration of CVVH within first 72 h, heart rate (tachycardia), need of catecholamine support, long surgery duration and combined cardiac surgery. This analysis suggests that CVVH must be initiated as soon as possible when ARF with diuretic resistance occurs in patients after cardiac surgery and must be continued as long as possible for the first 3 days.
These factors warrant larger prospective studies to assess whether they are of clinical relevance for therapeutic decisions in this clinical context to further improve the quality of care these patients deserve when ARF occurs after cardiac surgery. Nevertheless, it will be difficult to develop because of ethical problems and very low number of patients suffering from ARF with cardiogenic shock after cardiac surgery with CPB.
Finally, these results would justify and lead to extend the use of CRRT by CVVH in patients who present with ARF and diuretic drug resistance with cardiogenic shock after cardiac surgery with CPB.
